681667

Wnt Agonist II, SKL2001

The Wnt Agonist II, SKL2001 controls the biological activity of Wnt. This small molecule/inhibitor is primarily used for Biochemicals applications.

• 同義詞: Wnt Agonist II, SKL2001, 5-(Furan-2-yl)-N-(3-(1H-imidazol-1-yl)propyl)-1,2-oxazole-3-carboxamide, Wnt Pathway Activator VII
• 經驗公式（希爾表示法）: C₁₄H₁₄N₄O₃
• CAS號碼: 909089-13-0
• 分子量：: 286.29
• MDL號碼: MFCD14733081
• 分類程式碼代碼: 12352200
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥95% (HPLC)
• 形狀: solid
• 製造商／商標名: Calbiochem^®
• 儲存條件: OK to freeze; protect from light
• 顏色: pink-red
• 溶解度: DMSO: 100 mg/mL, clear, red
• 運輸包裝: ambient
• 儲存溫度: 2-8°C
• SMILES 字串: O=C(C1=NOC(C2=CC=CO2)=C1)NCCCN3C=NC=C3
• InChI: 1S/C14H14N4O3/c19-14(16-4-2-6-18-7-5-15-10-18)11-9-13(21-17-11)12-3-1-8-20-12/h1,3,5,7-10H,2,4,6H2,(H,16,19)
• InChI 密鑰: PQXINDBPUDNMPE-UHFFFAOYSA-N

描述

一般說明

A cell-permeable imidazolyl-isoxazolamide compound that upregulates β-catenin-regulated transcription (CRT; Effective conc. 10 - 40 µM) by blocking/disrupting β-catenin and Axin interaction, thereby preventing β-catenin phosphorylation (Ser³³/Ser³⁷/Thr⁴¹/Ser⁴⁵) and proteasomal degradation, without affecting the activities of GSK-3α/β or 18 other kinases (≤8.5% inhibition by 10 µM SKL2001). Wnt pathway activation by SKL2001 is shown to effectively promote osteoblastogenesis in both human and murine mesenchymal cultures (10 to 40 µM) as well as suppress MDI- (dexamethasone and insulin) stimulated adipogenesis of murine 3T3-L1 preadipocytes (5 to 30 µM).

包裝

Packaged under inert gas

警告

Toxicity: Standard Handling (A)

其他說明

Gwak, J., et al. 2012. Cell Res.22, 237.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable